MT-601
Lymphoma (post anti-CD19 CAR-T relapse or ineligible)
Phase 1Active
Key Facts
Indication
Lymphoma (post anti-CD19 CAR-T relapse or ineligible)
Phase
Phase 1
Status
Active
Company
About Marker Therapeutics
Marker Therapeutics is advancing a differentiated cell therapy platform that harnesses the natural T-cell repertoire without genetic modification. The company's lead candidate, MT-601, targets six tumor-associated antigens and is in Phase 1 for lymphoma patients who have failed or are ineligible for CAR-T therapy. Its strategy focuses on addressing the significant unmet need in solid tumors and relapsed hematologic malignancies with a potentially safer, more durable therapeutic approach, leveraging foundational research from Baylor College of Medicine.
View full company profile